Vinblastine sulfate

For research use only. Not for use in humans.

製品コードS4505 別名:NSC49842

Vinblastine sulfate化学構造

分子量(MW):909.05

Vinblastine sulfate inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer.

サイズ 価格(税別) 在庫  
JPY 13600 あり
JPY 43000 あり
JPY 114300 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(15)

製品安全説明書

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

生物活性

製品説明 Vinblastine sulfate inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer.
ターゲット
nAChR [1]
(Adrenal Chromaffin Cells)
8.9 μM
体外試験

The average terminal half-lives of Vinblastine is 14.3 h. When incubated in freshly isolated rat hepatocytes, VLB penetrates rapidly and intensely into the cells, probably through a passive diffusion mechanism followed by tight cellular binding[3]. Vinblastine inhibits the angiogenic response induced by adrenomedullin and is also positive for mitotic slippage, causing micronuclei in mononucleate cells with cytokinesis block[4]. vinblastine gives significant increase in micronucleated mononucleated cells at concentrations that produced approximately 50% cell death and cytostasis or less as calculated using RPD, RICC and RCC[2].

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
COLO 320 human colorectal carcinoma cell line M32ydGZ2dmO2aX;uJIF{e2G7 MlzzTY4hfmm2cn:gZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDrbYxtKDVyJTDv[kBEV0yRIEOyNEBpfW2jbjDjc4xwemWldHHsJINiemOrbn;tZUBk\WyuIHzpcoUtKEWFNUC9NE4xQCEQvF2= Mo[yNVI{PjF|OUe=
LNCaP human prostate cancer cell line M3fCUGZ2dmO2aX;uJIF{e2G7 Mom2TY4hfmm2cn:gZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDrbYxtKDVyJTDv[kBNVkOjUDDoeY1idiCycn;zeIF1\SClYX7j[ZIh[2WubDDsbY5mNCCHQ{WwQVAvPSEQvF2= NWnnTpREOTJ|NkGzPVc>
K562 cell NWfPe|VZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmWyTY4hfmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4h[2i{b37pZ{BugWWub3flco92eyCuZYXr[Y1q[SCNNU[yJINmdGxiZ4Lve5RpNCCLQ{WwQVAvODBzIN88US=> NFTSSWIyOjh3Mke2PC=>
T47D cells MoWySpVv[3Srb36gZZN{[Xl? MnX4TY4hfmm2cn:gZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDrbYxtKDVyJTDv[kBVPDeGIHj1cYFvKGK{ZXHzeEBlfWO2YXygZ4Fz[2mwb33hJINmdGxibHnu[UwhTUN3ME2wMlA5KM7:TR?= NVfBWIRTOTJ|NkGzPVc>
K562 cell NYLrcXN1WHKxbHnm[ZJifGmxbjDhd5NigQ>? MnXuOFghcA>? M2TjSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczDh[pRmeiB2ODDodpMtKEmFNUC9NE4xODFizszN M1\JPFE6OjJyMEG4
ACHN cells MX7DfZRwfG:6aXPpeJkh[XO|YYm= M1rucVQ5KGh? M{\zTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGFEUE5iY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2yNk44KM7:TR?= NFLte|cyQTR4N{i3Oy=>
A375 cells NI\QbFNEgXSxdH;4bYNqfHliYYPzZZk> MlTtOFghcA>? MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;Nz6yJO69VQ>? M1K4XVE6PDZ5OEe3
C32 cells NUH3R4pqS3m2b4TvfIlkcXS7IHHzd4F6 M{L3SFQ5KGh? M3nZXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGM{OiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUOg{txO M1LPVVE6PDZ5OEe3
LNCAP cells M2X4WWN6fG:2b4jpZ4l1gSCjc4PhfS=> NH76UmQ1QCCq NH7Mc3BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVI6NjNizszN MnzrNVk1Pjd6N{e=
Huh-7D12 cells NYjNR3A1S3m2b4TvfIlkcXS7IHHzd4F6 Ml\OOFghcA>? MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeYguP0RzMjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVQ2NjZizszN NXzKNVlLOTl2Nke4O|c>
COR-L23 cells M2HHfGN6fG:2b4jpZ4l1gSCjc4PhfS=> NF\IS3g1QCCq NES4UlBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEV1JvTEKzJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:PDVwNTFOwG0> NV72WIdYOTl2Nke4O|c>
142BR cells MUjDfZRwfG:6aXPpeJkh[XO|YYm= NVHjWmtrPDhiaB?= MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOFJDWiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUO3MlYh|ryP MmixNVk1Pjd6N{e=
HT-29 cells NWXTfVNnS3m2b4TvfIlkcXS7IHHzd4F6 MXG0PEBp MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuOVUh|ryP NUfYUnV1OjF7MkC3OlI>
A549 cells MVzQdo9tcW[ncnH0bY9vKGG|c3H5 M3G4NlQ5KGh? MnLYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:Oi5|NjFOwG0> MUmyNlU1PjZ5NB?=
DU145 cells Mn2zVJJwdGmoZYLheIlwdiCjc4PhfS=> MlP6OFghcA>? MkTjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGVUG0OUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTRwMkWg{txO M{CzeFIzPTR4Nke0
SK-MEL-5 cells MU\Qdo9tcW[ncnH0bY9vKGG|c3H5 NXnJeXBiPDhiaB?= MnHKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3NSWwuPSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUGuO|Qh|ryP Mn3BNlI2PDZ4N{S=
HepG2 cells NWP0SmN3WHKxbHnm[ZJifGmxbjDhd5NigQ>? MX60PEBp MnHIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMU[g{txO NF7UPVIzOjV2Nk[3OC=>
HT-29 cells NEfjUJNRem:uaX\ldoF1cW:wIHHzd4F6 NETGbZM1QCCq MoD2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTFzLkG4JO69VQ>? NG\6Om0zOjV2Nk[3OC=>
MCF7 cells MUPQdo9tcW[ncnH0bY9vKGG|c3H5 NGPmbHY1QCCq MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDhd5NigSxiSVO1NF0zPC5yODFOwG0> NUW1RYJ5OjJ3NE[2O|Q>
MDA-MB-231 cells M2q5cHBzd2yrZnXyZZRqd25iYYPzZZk> M1niT|Q5KGh? MoHmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFNiYYPzZZktKEmFNUC9N|EvPTJizszN MUWyNlU1PjZ5NB?=
rat REF52 cells NYj0UWo{TnWwY4Tpc44h[XO|YYm= M3v5OlAvOSEQvF2= MXizNEBucW6| NHPiR5RKdmS3Y4Tpc44hd2ZibXnjdo91fWK3bHWg[IVxd2y7bXXybZpifGmxbjDpckBz[XRiUlXGOVIh[2WubIOgZZQhOC5zIIXNJIFnfGW{IEOwJI1qdnNiYomg[ox2d3Knc3PlcoNmKGG|c3H5 MlX2NlM6PDd6Mk[=
HepG2 cells M4\IWmN6fG:2b4jpZ4l1gSCjc4PhfS=> MXy3NkBp NWLKeIJZS3m2b4TvfIlkcXS7IHHnZYlve3RiYXTybYFugWOrbj3y[ZNqe3SjboSgbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlA2PiEQvF2= NFS1WJAzOzdyOECxNC=>
HepG2 cells NF;YWnFEgXSxdH;4bYNqfHliYYPzZZk> MWm3NkBp MoPRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjBzOTFOwG0> MX6yN|cxQDBzMB?=
K562 cells M4LONGN6fG:2b4jpZ4l1gSCjc4PhfS=> MoDQO|IhcA>? Mln5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODF4IN88US=> M1nUb|I{PzB6MEGw
MDA-MB-231 cells NVvrPGhHS3m2b4TvfIlkcXS7IHHzd4F6 NVjWOmlFPzJiaB?= MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFg{KM7:TR?= M1TTZVI{PzB6MEGw
MCF7 cells NXrRZZM3S3m2b4TvfIlkcXS7IHHzd4F6 NFHPOlU4OiCq M1ixWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByNzFOwG0> MWSyN|cxQDBzMB?=
SCL6 cells NETNXHBEgXSxdH;4bYNqfHliYYPzZZk> M{DsV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNEVDZiY3XscJMh[nliTWTUJIF{e2G7LDDFSFUxRTZwMTFOoI0> NUSxb|RGOTJ6OECzNVQ>
SCL9 NUXxeYZ2S3m2b4TvfIlkcXS7IHHzd4F6 M4PPN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNEVDliY3XscJMh[nliTWTUJIF{e2G7LDDFSF02NjNizszN NEmyWI4yOjh6MEOxOC=>
KATO III cells Mkn5R5l1d3SxeHnjbZR6KGG|c3H5 MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRXRQKEmLSTDj[YxteyCkeTDNWHQh[XO|YYmsJGVFPTB;Nj6xJO69VQ>? M2C1bVEzQDhyM{G0
NUGC4 cells M3LsO2N6fG:2b4jpZ4l1gSCjc4PhfS=> NYPjeHNLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVlWJQ{SgZ4VtdHNiYomgUXRVKGG|c3H5MEBGTDVyPUWuN{DPxE1? MmXoNVI5QDB|MUS=
UACC903 cells NYrIWWRDS3m2b4TvfIlkcXS7IHHzd4F6 MWO0PEBp NX;2U5N2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXUGFQ{mwN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTFwNkWg{txO NXrNSFNkOjF7MkC3OlI>
K562 cells MoLnSpVv[3Srb36gZZN{[Xl? M{Dx[mlvcGmkaYTpc44hd2ZidIXieYxqdiCyb3z5cYVzcXqjdHnvckBqdiCqdX3hckBMPTZ{IHPlcIx{NCCLQ{WwQVAvOTNizszN M13qeVIxPTR4OUiw
BxPC3 cells M3j4U3Bzd2yrZnXyZZRqd25iYYPzZZk> NFjtPHE1QCCq NGfjRWJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFL4VGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MT6xN{DPxE1? MYmyNlU1PjZ5NB?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
GRP78 ; 

PubMed: 19674193     


Taxol and vinblastine induce GRP78 expression in breast cancer cells. (A) ZR75-30 cells were treated with taxol and vinblastine for 24 hrs. Cell lysates were harvested and subjected to Western blot analysis with anti-GRP78 antibody. -actin was probed as a loading control. (B) Western blot analysis of GRP78 expression in response to taxol and vinblastine treatments in T47D cells. (C) Western blot analysis of GRP78 expression in response to taxol and vinblastine treatments in MCF-7 cells. (D) MCF-7 cells were treated with 0.5 μM taxol and 0.1 μM vinblastine for indicated hours. Cell lysates were harvested and subjected to Western blot analysis with anti-GRP78 antibody.

p-eIF2; 

PubMed: 19674193     


MCF-7 cells were treated with 0.5 μM taxol and 0.1 μM vinblastine for indicated periods. Total proteins were harvested and subjected to Western blot analysis of the phosphorylated eIF2α.

p-JNK / c-Caspase-7 / c-PARP ; 

PubMed: 19674193     


MCF-7 cells were treated with indicated doses of taxol and vinblastine for 24 hrs. Total proteins were harvested and subjected to Western blot analysis of the phosphorylated JNK, cleaved caspase-7 and PARP.

ERK / p-ERK / Mcl-1 / Bad / Bid / Noxa ; 

PubMed: 20371726     


Expression of Bcl-2 family members and activation of MAPK proteins in the panel of cell lines. The indicated cell lines were either undamaged or incubated with 2.2 μM vinblastine for 4 h. Lysates were analyzed by immunoblotting for expression of the indicated proteins.

19674193 20371726
Immunofluorescence
α-tubulin / Acetyl tubulin ; 

PubMed: 30120268     


Differentiated SH-SY5Y cells were incubated in the absence and presence of indibulin (25 nM), vinblastine (10 nM) and colchicine (10 nM) for 24 h. Cells were fixed and processed for immunostaining with antibodies against α-tubulin (green) and acetylated tubulin (red). Cells were observed at two magnifications under a microscope. Scale bar = 100 and 10 μm in low (Left panel) and high (Right panel) magnification, respectively.

30120268
Growth inhibition assay
Cell viability; 

PubMed: 27114800     


Panel (A) shows cell viability (%) of the cells after 24 and 48 hrs incubation with vinblastine (0-100 nM) or docetaxel (0-100 nM). 

27114800
体内試験 Vinblastine is a widely used anticancer drug with undesired side effects [6]. A combination of VBL and RAP at very low doses against human HCC gets a satisfactory antiangiogenic effect in vivo[4]. The clinically relevant dose of vinblastine inhibits palmitoylation of tubulin in vivo in CEM cells (effect on depalmitoylation of tubulin)[5].

お薦めの試験操作(参考用のみ)

細胞試験:

[2]

- 合併
  • 細胞株: Chinese hamster ovary (CHO) cells
  • 濃度: 1% (v/v) (dissolved in DMSO)
  • 反応時間: 3h
  • 実験の流れ:

    Six-well treatment plates are set up that contained 5 × 104 cells/mL in each well, suspended in 3 mL culture medium, and these are treated with vinblastine for 3 h followed by 21 h growth.


    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (110.0 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 909.05
化学式

C46H58N4O9.H2SO4

CAS No. 143-67-9
保管
in solvent
別名 NSC49842
Smiles CCC1(O)CC2CN(CCC3=C([NH]C4=CC=CC=C34)C(C2)(C(=O)OC)C5=C(OC)C=C6N(C)C7C(O)(C(OC(C)=O)C8(CC)C=CCN9CCC7(C89)C6=C5)C(=O)OC)C1.O[S](O)(=O)=O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(余分な消耗を考慮し動物一匹分の量を用意することをお勧めします。)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロットごとに組成が異なるため、セレックから完全に溶解できる組成をお求めください。)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02840409 Recruiting Drug: Vinblastine|Drug: Bevacizumab Low Grade Glioma The Hospital for Sick Children|Hoffmann-La Roche August 2016 Phase 2
NCT02670707 Recruiting Drug: Cytarabine|Drug: Vinblastine/prednisone Langerhans Cell Histiocytosis Baylor College of Medicine March 7 2016 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須
Tags: Vinblastine sulfateを買う | Vinblastine sulfate ic50 | Vinblastine sulfate供給者 | Vinblastine sulfateを購入する | Vinblastine sulfate費用 | Vinblastine sulfate生産者 | オーダーVinblastine sulfate | Vinblastine sulfate化学構造 | Vinblastine sulfate分子量 | Vinblastine sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID